COVID-19 Vaccination and Non–COVID-19 Mortality Risk — Seven Integrated Health Care Organizations, United States, December 14, 2020–July 31, 2021

Abstract

No. (%) mRNA vaccine* Janssen vaccine Pfizer-BioNTech vaccine recipients Moderna vaccine recipients Unvaccinated comparison group , Janssen vaccine recipients Unvaccinated comparison group Total 3,452,126 (100.0) 2,604,066 (100.0) 3,243,112 (100.0) 342,169 (100.0) 1,346,445 (100.0) Age group, yrs 12-17 316,587 (9.2) NA 311,445 (9.6) NA NA * Among Pfizer-BioNTech COVID-19 vaccine recipients, 2,980,152 received the second dose by May 31, 2021; among Moderna COVID-19 vaccine recipients, 2,362,157 received the second dose by May 31, 2021. Unvaccinated comparison group included unvaccinated persons and COVID-19 vaccine recipients before COVID-19 vaccination. The assignment of index dates allowed COVID-19 vaccinees to contribute unvaccinated person-time before vaccination, thus avoiding immortal time bias. mRNA vaccines included Pfizer-BioNTech and Moderna COVID-19 vaccines.